Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2016
Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need. This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication.
Related Market Assessment Reports
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
